Abstract
The clinical efficacy of promising cocaine anti-craving medications was examined in combination with buprenorphine. Twenty-one opioid-dependent cocaine abusers were enrolled in a double-blind, 12-week trial in which they received on a daily basis buprenorphine (8 mg, s.l.) plus either desipramine (150 mg, p.o.), amantadine (300 mg, p.o.), or fluoxetine (60 mg, p.o.). Urine samples and self-reported drug use were obtained 1-3 times/week. The order of greatest patient retention across the 12 weeks was desipramine (83.3%) > amantadine (66.7%) > fluoxetine (20.0%). The desipramine and amantadine groups appeared to have greater increases in opioid- and cocaine-free urines than the fluoxetine group. These results suggest that desipramine and amantadine may facilitate greater opioid and cocaine abstinence than fluoxetine.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Amantadine / adverse effects
-
Amantadine / therapeutic use*
-
Buprenorphine / adverse effects
-
Buprenorphine / therapeutic use*
-
Cocaine*
-
Desipramine / adverse effects
-
Desipramine / therapeutic use*
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Drug Administration Schedule
-
Drug Therapy, Combination
-
Female
-
Fluoxetine / adverse effects
-
Fluoxetine / therapeutic use*
-
Humans
-
Male
-
Middle Aged
-
Narcotic Antagonists / adverse effects
-
Narcotic Antagonists / therapeutic use*
-
Substance Abuse Detection
-
Substance-Related Disorders / psychology
-
Substance-Related Disorders / rehabilitation*
-
Treatment Outcome
Substances
-
Narcotic Antagonists
-
Fluoxetine
-
Buprenorphine
-
Amantadine
-
Cocaine
-
Desipramine